Stadler W M - Center for Personalized Therapeutics, The University of Chicago

基本信息

浏览量：1

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 78 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Doxorubicin Plus The Igf-1r Antibody Cixutumumab In Soft Tissue Sarcoma: A Phase I Study Using The Tite-Crm Model (Vol 26, Pg 1459, 2015)

R. Chugh,K. A. Griffith,E. J. Davis,D. G. Thomas, J. D. Zavala, G. Metko,B. Brockstein,S. D. Undevia,W. M. Stadler,S. M. Schuetze

ANNALS OF ONCOLOGY（2019）

引用0浏览0引用

Correction to: Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model

R. Chugh,K.A. Griffith,E.J. Davis,D.G. Thomas, J.D. Zavala, G. Metko,B. Brockstein,S.D. Undevia,W.M. Stadler,S.M. Schuetze

Annals of Oncology（2019）

引用14浏览0WOS引用

CHANGES IN PROVIDER KNOWLEDGE AND PERCEPTIONS OF PHARMACOGENOMICS AFTER PARTICIPATION IN AN INSTITUTIONAL IMPLEMENTATION STUDY

B. A. Borden,K. Danahey, P. Galecki,L. Patrick-Miller, R. Wellmann, S. Lee,M. Siegler, M. J. Sorrentino,W. M. Stadler,D. O. Meltzer,M. J. Ratain,P. H. O'Donnell

CLINICAL PHARMACOLOGY & THERAPEUTICSno. SUPnan (2018): S61-S61

引用0浏览0引用

Patient Perceptions of Care as Influenced by a Large Institutional Pharmacogenomic Implementation Program

R P McKillip,B A Borden, P Galecki,S A Ham,L Patrick-Miller,J P Hall,S Hussain,K Danahey,M Siegler, M J Sorrentino, Y Sacro,A M Davis,

CLINICAL PHARMACOLOGY & THERAPEUTICSno. 1 (2017): 106-114

引用27浏览0WOS引用

Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing

P. H. O'Donnell, N. Wadhwa,K. Danahey,B. A. Borden,S. M. Lee,J. P. Hall, C. Klammer,S. Hussain,M. Siegler, M. J. Sorrentino,A. M. Davis, Y. A. Sacro,

Clinical pharmacology and therapeutics/Clinical pharmacology & therapeuticsno. 5 (2017): 859-869

引用67浏览0WOS引用

CHARACTERIZATION OF NON-T CELL-INFLAMED BLADDER CANCER TO ENHANCE IMMUNOTHERAPY RESPONSE

R. F. Sweis,S. Spranger,R. Bao,G. P. Paner,W. M. Stadler,G. D. Steinberg,T. F. Gajewski

CLINICAL PHARMACOLOGY & THERAPEUTICSno. S1 (2017): S14-S14

引用0浏览0引用

Phase II study of FK228 in patients with hormone refractory prostate cancer (HRPC)

R Molife,S Patterson,C Riggs,C Higano,W M Stadler, D P Dearnaley,Chris Parker,W Mcculloch, A Shalaurov,J Debono

Journal of Clinical Oncology（2016）

引用9浏览0引用

Prediction of PARP inhibitor response and resistance utilizing a CTC phenotypic classifer in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results from the NCI 9012 trial

F.Y. Feng,S. Daignault-Newton,A. Jendrisak,Y. Wang,S. Greene,A. Rodriguez,J. Lee,L. Dugan,J. Siddiqui,J. Louw,C. Johnson,P. Twardowski,

ANNALS OF ONCOLOGY（2016）

引用0浏览0引用

Phase II study of eribulin in platinum-treated, tubulin naive advanced urothelial cancer (UC) - A California Cancer Consortium trial (NCI/CTEP 7435)

D. I. Quinn,P. W. Twardowski, Y. E. Wei,S. G. Groshen,T. B. Dorff,A. M. Aparicio,W. M. Stadler,D. R. Gandara,P. N. Lara,E. M. Newman

EUROPEAN JOURNAL OF CANCER（2013）

引用0浏览0引用

Estimation of renal cell carcinoma treatment effects from disease progression modeling

M L Maitland,K Wu,M R Sharma,Y Jin,S P Kang,W M Stadler,T G Karrison,M J Ratain,R R Bies

CLINICAL PHARMACOLOGY & THERAPEUTICSno. 4.0 (2013): 345-351

引用13浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn